RecruitingVaccine ReactionZosterSystemic Lupus Erythematosus
Reduced Vaccine Response to HZ/su in SLE
Eligible age
50+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.
Sponsor: Seoul National University Hospital
You may qualify if…
- ✓ Males or females ≥ 50 years of age at time of consent
- ✓ ≥ 4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (14, 15)
- ✓ Clinically stable SLE
- ✓ Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks
- ✓ Corticosteroid use: ≥ 5mg/day of prednisolone equivalent
- ✓ Antimalarials (≤ 400 mg/day)
- ✓ Azathioprine (≤ 3 mg/kg/day)
- ✓ Mycophenolate mofetil (≤ 3 mg/day)
You may not qualify if…
- ✕ Pregnant or lactating females
- ✕ Acute infection with temperature \>38C at the time of vaccination
- ✕ Previous anaphylactic response to vaccine components or to egg
- ✕ History of Guillain-Barre syndrome or demyelinating syndromes
- ✕ Any condition including laboratory abnormality which places the subject at unacceptable risk
- ✕ Subjects who decline to participate
Source: ClinicalTrials.gov · NCT07636044 · last updated 2026-06-09